Gene Therapy Trials In EU Delayed By Environmental Considerations
Executive Summary
Pharmaceutical companies in the EU are becoming keener to experiment with genetically-modified advanced therapy medicinal products in patients, but they are finding it hard to navigate through the maze of environmental risk assessment procedures in each member state.